关注
Mark Sliwkowski
Mark Sliwkowski
Distinguished Staff Scientist (Genentech, retired). Denali Therapeutics
在 dnli.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Untangling the ErbB signalling network
Y Yarden, MX Sliwkowski
Nature reviews Molecular cell biology 2 (2), 127-137, 2001
87682001
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate
GD Lewis Phillips, G Li, DL Dugger, LM Crocker, KL Parsons, E Mai, ...
Cancer research 68 (22), 9280-9290, 2008
19662008
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
J Stamos, MX Sliwkowski, C Eigenbrot
Journal of biological chemistry 277 (48), 46265-46272, 2002
15542002
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
JR Junutula, H Raab, S Clark, S Bhakta, DD Leipold, S Weir, Y Chen, ...
Nature biotechnology 26 (8), 925-932, 2008
14842008
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin, KD Carey, FF Vajdos, DJ Leahy, AM De Vos, MX Sliwkowski
Cancer cell 5 (4), 317-328, 2004
14152004
Identification of Heregulin, a Specific Activator of p185erbB2
WE Holmes, MX Sliwkowski, RW Akita, WJ Henzel, J Lee, JW Park, ...
Science 256 (5060), 1205-1210, 1992
13131992
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors
AW Burgess, HS Cho, C Eigenbrot, KM Ferguson, TPJ Garrett, DJ Leahy, ...
Molecular cell 12 (3), 541-552, 2003
13102003
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus, RW Akita, WD Fox, GD Lewis, B Higgins, PI Pisacane, ...
Cancer cell 2 (2), 127-137, 2002
11082002
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
BQ Shen, K Xu, L Liu, H Raab, S Bhakta, M Kenrick, KL Parsons-Reponte, ...
Nature biotechnology 30 (2), 184-189, 2012
10792012
Treatment of HER2-positive breast cancer: current status and future perspectives
CL Arteaga, MX Sliwkowski, CK Osborne, EA Perez, F Puglisi, L Gianni
Nature reviews Clinical oncology 9 (1), 16-32, 2012
10782012
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
MX Sliwkowski, JA Lofgren, GD Lewis, TE Hotaling, BM Fendly, JA Fox
Seminars in oncology 26 (4 Suppl 12), 60-70, 1999
9841999
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941
TT Junttila, RW Akita, K Parsons, C Fields, GDL Phillips, LS Friedman, ...
Cancer cell 15 (5), 429-440, 2009
9822009
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
MX Sliwkowski, G Schaefer, RW Akita, JA Lofgren, VD Fitzpatrick, ...
Journal of Biological Chemistry 269 (20), 14661-14665, 1994
9081994
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
M Pegram, S Hsu, G Lewis, R Pietras, M Beryt, M Sliwkowski, D Coombs, ...
Oncogene 18 (13), 2241-2251, 1999
8951999
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
RJ Pietras, J Arboleda, DM Reese, N Wongvipat, MD Pegram, L Ramos, ...
Oncogene 10 (12), 2435-2446, 1995
8731995
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy
ST Lee-Hoeflich, L Crocker, E Yao, T Pham, X Munroe, KP Hoeflich, ...
Cancer research 68 (14), 5878-5887, 2008
7602008
Antibody therapeutics in cancer
MX Sliwkowski, I Mellman
Science 341 (6151), 1192-1198, 2013
7012013
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
IE Krop, M Beeram, S Modi, SF Jones, SN Holden, W Yu, S Girish, ...
Journal of Clinical Oncology 28 (16), 2698-2704, 2010
6862010
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
TT Junttila, G Li, K Parsons, GL Phillips, MX Sliwkowski
Breast cancer research and treatment 128, 347-356, 2011
6202011
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin
CD Austin, AM De Mazière, PI Pisacane, SM van Dijk, C Eigenbrot, ...
Molecular biology of the cell 15 (12), 5268-5282, 2004
5692004
系统目前无法执行此操作,请稍后再试。
文章 1–20